

Kidney Cancer (Clear Cell Carcinoma) Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: _____

ICD-10 Code: _____

First Line of Therapy (1st Line)

- Stages IV and Recurrent
 - Unfavorable Risk
 - Nivolumab (Opdivo) and cabozantinib (Cabometyx)
 - Nivolumab (Opdivo) and ipilimumab (Yervoy)
 - Pembrolizumab (Keytruda) and axitinib (Inlyta)
 - Favorable Risk
 - Nivolumab (Opdivo) and cabozantinib (Cabometyx)
 - Pembrolizumab (Keytruda) and axitinib (Inlyta)
-

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631

Last review: 5/6/2025 | Effective date: 7/14/2025

© 2025 Carelon Medical Benefits Management